Skip to main content

Market Overview

Hologic Downgraded By BofA As Cynosure Headwinds Persist

Share:
Hologic Downgraded By BofA As Cynosure Headwinds Persist

An 8-K filed late Wednesday suggests Hologic, Inc. (NASDAQ: HOLX)’s headed for harder times.

The Analyst

Bank of America Merrill Lynch analyst Derik de Bruin downgraded Hologic from Buy to Neutral and cut the price target from $47 to $42.

The Thesis

Hologic subsidiary Cynosure is expected to lose about $15 million in the fourth quarter in forfeited sales and refunds related to its voluntary recall of Vitalia, as well as reduced sales of MonaLisa Touch. The company previously guided for a $7-million Vitalia-related revenue hit.

Nonetheless, Hologic expects strong top-line growth in other core segments to offset the impact to Cynosure. The company reaffirmed revenue guidance between $800 million and $815 million.

Given poor visibility and continued headwinds from Cynosure — coupled with uncertainty around a Quest Diagnostics Inc (NYSE: DGX) contract renewal — Bank of America is withholding its recommendation.

“At this point the fiscal ’19 financial impact of the CYNO recalls and FDA concerns surrounding the VR market are hard to quantify, as it is unclear when HOLX may reintroduce Vitalia or to what extent MLT sales will be reduced,” de Bruin said in a Thursday note. (See his track record here.) 

BofA cut its 2019 bottom-line forecasts from $2.45 to $2.37 to account for lower sales, higher share count and higher interest expense. Hologic’s core business does appear solid, de Bruin said. 

Price Action

Hologic shares were trading 1.18 percent higher at $39.51 at the time of publication Thursday.

Related Links:

WHO Deems The Products Of These Diagnostic Companies 'Essential'

Hologic's SculpSure Body Contouring Treatment Scores Distribution Win

Photo courtesy of Hologic. 

Latest Ratings for HOLX

DateFirmActionFromTo
Apr 2021JefferiesMaintainsBuy
Feb 2021BairdMaintainsBuy
Dec 2020Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

 

Related Articles (HOLX)

View Comments and Join the Discussion!

Posted-In: Bank of America Merrill Lynch Derik de BruinAnalyst Color Downgrades Price Target Analyst Ratings Best of Benzinga

Latest Ratings

StockFirmActionPT
SAMEvercore ISI GroupMaintains1,500.0
SEAutonomous ResearchInitiates Coverage On378.0
ALHCMorgan StanleyInitiates Coverage On36.0
ALHCRaymond JamesInitiates Coverage On30.0
HAEMorgan StanleyDowngrades83.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com